Method for identifying altered vitamin d metabolism
OwnerDonald L. Trump, Josephia Muindi +2inventors
InventorsDonald L. Trump, Josephia Muindi, Lionel J. Coignet, Candace S. Johnson
Life of this patent
Estimating the term…
Abstract
A method is provided for identifying an individual as having altered vitamin D metabolism comprising analyzing a biological sample from the individual for the presence of CYP24 SNPs and/or aberrantly spliced CYP24 mRNA. The presence of the SNPs and/or the aberrantly spliced CYP24 mRNA indicates that the individual has altered vitamin D metabolism. Also provided are methods for customizing dosages of biologically active vitamin D compounds for individuals who are determined to have altered vitamin D metabolism.
Claims18
A method for determining whether an individual is likely to have altered calcitriol catabolism, wherein the method comprises:
- a) obtaining a biological sample from an individual;
- and
- b) determining the presence or absence of:
- i) at least one single nucleotide polymorphisms (SNPs) listed in Table 2;
- ii) aberrantly spliced CYP24 mRNA;
- iii) calcitriol insensitive splicing;
- or
- iv) combinations of i) through iii);
- wherein determining i), ii) or a combination thereof, is indicative that the individual is likely to have reduced calcitriol catabolism relative to an individual who does not have i) or ii), and wherein the presence of iii) is indicative that the individual is likely to have high calcitriol catabolism relative to an individual who does not have iii).
A method for determining, for an individual in need of vitamin D therapy, a dosing regime for calcitriol, a calcitriol precursor, or a vitamin D analog compound, wherein the vitamin D analog compound generates less of a calcemic response than calcitriol, the method comprising:
- a) obtaining a biological sample from an individual;
- and
- b) determining in the biological sample the presence or absence of:
- i) at least one SNP listed in Table 2;
- ii) aberrantly spliced CYP24 mRNA;
- or
- iii) calcitriol insensitive splicing;
- or
- iv) combinations of i) through iii);
- wherein the presence of i) or ii), or a combination thereof, is indicative that the individual is a candidate for a lower dose of the calcitriol, the calcitriol precursor, or the vitamin D analog, relative to an individual in need of the vitamin D therapy who does not have i) or ii), and wherein the presence of iii) is indicative that the individual is a candidate for a higher dose of the calcitriol or the calcitriol precursor, relative to an individual in need of the vitamin D therapy who does not have iii).
Dependencies are inferred from the claim text.